How do current analyst price targets, averaging $8.92 as of August 2025, compare to RANI's share price post-Q3 2025 results?

As of November 6, 2025, following the release of its Q3 2025 financial results, Rani Therapeutics Holdings, Inc. (RANI) Class A common stock was trading at $2.27 per share.1 This share price is significantly below the average analyst price target of $8.92, which was established as of August 6, 2025, with a projection date extending to August 6, 2026.2

The analyst price targets for RANI in August 2025 ranged from a low of $5.05 to a high of $12.60.2 The current trading price represents a substantial discount to even the lowest end of this projected range, indicating a considerable gap between market valuation and analyst expectations at that time.

Rani Therapeutics reported its Q3 2025 financial results on November 6, 2025.3 Key updates included the announcement of a collaboration with Chugai Pharmaceutical Co. potentially valued at up to $1.085 billion and the completion of a $60.3 million oversubscribed private placement.3 The company also extended its cash runway into 2028.3 Despite these developments, the market price remained well below the average analyst target.